Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in February 2027Marks
Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectationsRUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025,
Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total operating expenses of approximately US$74.6 million, in line with third quarter
First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was well-tolerated, with benefits
Leiden, the Netherlands, September 29, 2026: Pharming (NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the Board of Directors and Fabrice Chouraqui have
If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or moreDecision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least
Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results
FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are expected to be
Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced that its management will participate in the following investor conferences in the month of September:
Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan
Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22% in a single session.NEW YORK, Aug. 7, 2026 /PRNewswire/ -- A 22%
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pharming Group N.V. ("Pharming" or the
Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR) investors concerning the Company’s possible violations of federal
The Law Offices of Frank R. Cruz announces an investigation of Pharming Group N.V. ("Pharming" or the "Company") (NASDAQ: PHAR) on behalf of investors concerning the Company’s possible violations of
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pharming Group (NASDAQ:PHAR) stock dropped 22% on July 30, 2026, after the Company reported second-quarter revenue of $90.2 million -- down 3% year-over-year -- and cut its
